Lurasidone a new atypical antipsychotic

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Lurasidone is a new atypical antipsychotic that is effective for short- and long-term treatment of patients with schizophrenia. It joins ziprasidone and aripiprazole as 'metabolically friendly' treatments but, unlike ziprasidone, has a low risk of causing QT prolongation. Possible side effects include akathisia and parkinsonism.

Original languageEnglish
Pages (from-to)56-57
Number of pages2
JournalMedicine Today
Volume17
Issue number9
Publication statusPublished - 1 Sep 2016

Cite this